Response  	Response  	 NN	O
predictive  	predictive  	 JJ	B-NP
biomarkers  	biomarkers  	 NN	I-NP
to  	to  	 TO	O
targeted  	targeted  	 JJ	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
oncology  	oncology  	 JJ	B-NP
Cancer  	Cancer  	 NNP	I-NP
kills  	kills  	 VBZ	O
147,500  	147,500  	 CD	O
people  	people  	 NNS	O
each  	each  	 DT	O
year  	year  	 NN	O
in  	in  	 IN	O
France 	France 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
personalized  	personalized  	 JJ	O
therapies  	therapies  	 NNS	O
and  	and  	 CC	O
more  	more  	 RBR	O
recently  	recently  	 RB	O
theranostics 	theranostics 	 JJ	O
,  	,  	 ,	O
completely  	completely  	 RB	O
changed  	changed  	 VBN	O
the  	the  	 DT	O
biological  	biological  	 JJ	B-NP
approach  	approach  	 NN	I-NP
to  	to  	 TO	O
this  	this  	 DT	O
disease 	disease 	 NN	O
.  	.  	 .	O
Thus 	Thus 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
already  	already  	 RB	O
well-known  	well-known  	 JJ	O
but  	but  	 CC	O
sparsely  	sparsely  	 RB	O
specific  	specific  	 JJ	O
serum  	serum  	 JJ	B-NP
markers  	markers  	 NNS	I-NP
are  	are  	 VBP	O
being  	being  	 VBG	O
replaced  	replaced  	 VBN	O
by  	by  	 IN	O
new  	new  	 JJ	O
tumor  	tumor  	 NN	B-NP
markers 	markers 	 NN	I-NP
,  	,  	 ,	O
predictive  	predictive  	 JJ	O
of  	of  	 IN	O
resistance  	resistance  	 NN	O
or  	or  	 CC	O
response  	response  	 NN	O
to  	to  	 TO	O
targeted  	targeted  	 JJ	O
therapies 	therapies 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
biomarkers  	biomarkers  	 NN	B-NP
is  	is  	 VBZ	O
performed  	performed  	 VBN	O
by  	by  	 IN	O
different  	different  	 JJ	O
technical  	technical  	 JJ	B-NP
approaches 	approaches 	 NNS	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
are  	are  	 VBP	O
essentially  	essentially  	 RB	O
based  	based  	 VBN	O
molecular  	molecular  	 JJ	B-NP
biology  	biology  	 NN	I-NP
assays 	assays 	 NN	I-NP
.  	.  	 .	O
These  	These  	 DT	O
determinations  	determinations  	 NNS	B-NP
are  	are  	 VBP	O
assessed  	assessed  	 VBN	O
in  	in  	 IN	O
France  	France  	 NNP	O
within  	within  	 IN	O
the  	the  	 DT	O
28  	28  	 CD	O
molecular  	molecular  	 JJ	B-NP
tumor  	tumor  	 NN	I-NP
genetics  	genetics  	 NNS	I-NP
platforms  	platforms  	 VBP	I-NP
approved  	approved  	 VBN	O
by  	by  	 IN	O
French  	French  	 NNP	O
National  	National  	 NNP	O
Cancer  	Cancer  	 NNP	O
Institute  	Institute  	 NNP	O
( 	( 	 -LRB-	O
INCa 	INCa 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
commonly  	commonly  	 RB	O
used  	used  	 VBN	O
assays  	assays  	 VBN	O
for  	for  	 IN	O
this  	this  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
molecular  	molecular  	 JJ	B-NP
diagnostics 	diagnostics 	 NNS	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
real-time  	real-time  	 JJ	B-NP
PCR 	PCR 	 NNP	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
sequencing 	sequencing 	 NN	B-NP
,  	,  	 ,	O
immunohistochemistry 	immunohistochemistry 	 NN	B-NP
,  	,  	 ,	O
FISH  	FISH  	 NNP	O
or  	or  	 CC	O
CISH 	CISH 	 NNP	B-NP
,  	,  	 ,	O
are  	are  	 VBP	O
relatively  	relatively  	 RB	O
difficult  	difficult  	 JJ	O
because  	because  	 IN	O
most  	most  	 JJS	O
of  	of  	 IN	O
them  	them  	 PRP	O
are  	are  	 VBP	O
based  	based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
formalin  	formalin  	 FW	O
fixed  	fixed  	 FW	B-NP
paraffin  	paraffin  	 FW	I-NP
embedded  	embedded  	 FW	I-NP
tumor  	tumor  	 FW	I-NP
tissues 	tissues 	 FW	I-NP
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
provides  	provides  	 VBZ	O
a  	a  	 DT	O
synthesis  	synthesis  	 NN	O
of  	of  	 IN	O
validated  	validated  	 JJ	O
theranostic  	theranostic  	 JJ	B-NP
biomarkers  	biomarkers  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
most  	most  	 RBS	O
used  	used  	 VBN	O
diagnostic  	diagnostic  	 JJ	B-NP
methods 	methods 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
also  	also  	 RB	O
draw  	draw  	 VB	O
a  	a  	 DT	O
point  	point  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
best  	best  	 RBS	O
incoming  	incoming  	 JJ	O
biomarkers  	biomarkers  	 JJ	B-NP
candidates  	candidates  	 NNS	I-NP
and  	and  	 CC	O
assays  	assays  	 NN	O
in  	in  	 IN	O
close  	close  	 JJ	O
development  	development  	 NN	O
using  	using  	 VBG	O
liquid  	liquid  	 JJ	B-NP
biopsies 	biopsies 	 NNS	I-NP
.  	.  	 .	O
